ITeos Therapeutics Inc (ITOS) concluded trading on Wednesday at a closing price of $10.06, with 13.6 million shares of worth about $136.82 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 23.74% during that period and on Wednesday the price saw a gain of about 17.94%. Currently the company’s common shares owned by public are about 38.27M shares, out of which, 35.99M shares are available for trading.
Stock saw a price change of 20.48% in past 5 days and over the past one month there was a price change of 42.29%. Year-to-date (YTD), ITOS shares are showing a performance of 30.99% which decreased to -42.65% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.80 but also hit the highest price of $18.13 during that period. The average intraday trading volume for ITeos Therapeutics Inc shares is 888.85K. The stock is currently trading 29.72% above its 20-day simple moving average (SMA20), while that difference is up 45.81% for SMA50 and it goes to 12.09% higher than SMA200.
ITeos Therapeutics Inc (NASDAQ: ITOS) currently have 38.27M outstanding shares and institutions hold larger chunk of about 112.55% of that.
The stock has a current market capitalization of $385.03M and its 3Y-monthly beta is at 1.43. It has posted earnings per share of -$3.23 in the same period. It has Quick Ratio of 14.13 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ITOS, volatility over the week remained 8.24% while standing at 6.10% over the month.
Stock’s fiscal year EPS is expected to rise by 15.94% while it is estimated to increase by 36.79% in next year. EPS is likely to grow at an annualized rate of 3.89% for next 5-years, compared to annual growth of -34.39% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on May 28, 2025 offering an Equal weight rating for the stock and assigned a target price of $12 to it. Coverage by Wedbush stated ITeos Therapeutics Inc (ITOS) stock as a Neutral in their note to investors on May 28, 2025, suggesting a price target of $12 for the stock. Stock get a Neutral rating from JP Morgan on May 13, 2025.
